For the first time ever, no young women in England died of cervical cancer. In the U.S., RFK Jr.’s vaccine skepticism stalls HPV progress

England recorded zero cervical cancer deaths among women aged 20 to 24 from 2020 to 2024, versus an estimated 23 deaths absent vaccination, according to a Lancet study. The authors say HPV vaccination has already prevented nearly 200 young women from dying from cervical cancer in England, with 88% to 90% coverage in the youngest cohort. The article also flags a U.S. uptake risk: only 61% of adolescents ages 13 to 17 have completed the HPV series, and vaccination initiation has stalled for three straight years.

Analysis

The investable signal is not the mortality print itself; it is the lagged validation that HPV vaccination has crossed from efficacy to durable population-level effectiveness. That matters because the market has treated Gardasil as a political and litigation story, while the underlying demand curve is likely to be driven more by school-entry compliance, pediatrician recommendation strength, and insurer reimbursement than by headline controversy. In other words, the long-duration cash flow is probably less elastic to current anti-vax rhetoric than the recent stock narrative implies, but the next 12–24 months still hinge on whether coverage can re-accelerate from a stalled base.

Second-order, the biggest loser from a weaker U.S. uptake is not just the vaccine manufacturer; it is the public-health system’s ability to keep screening costs and downstream oncology burden contained. If adolescent completion remains stuck in the low-60s, the benefit inflection seen in England will arrive later and more unevenly in the U.S., especially in rural and conservative-leaning states. That creates a bifurcation: states with strong school mandates and provider networks should see earlier normalization, while lagging regions preserve future treatment volumes for oncology, diagnostics, and gynecologic surgery over the next decade.

The litigation overhang is the near-term catalyst that can still overpower fundamentals, but it also creates an entry window for investors willing to look through 6–12 months of noise. Consensus likely underestimates how much of the U.S. market is already saturated in covered cohorts; the real upside is not from price but from closing the completion gap and from emerging-market expansion, which is currently underpenetrated. The contrarian risk is that policy sabotage in Washington becomes self-reinforcing and pushes adoption below the threshold needed to sustain the 80% target, making current consensus revenue models too optimistic for the next two vaccine cycles.

Key Decisions for Investors

• Long CHD as a relative beneficiary of normalized vaccine utilization and broader pediatric preventive-care spend; use a 6–12 month horizon and size modestly because the ticker is effectively a placeholder for defensive healthcare exposure, not a direct HPV catalyst.
• If available in the portfolio, pair long MRK against a short basket of litigation-sensitive healthcare sentiment names on any post-trial weakness; risk/reward favors buying fear if the stock de-rates on headline risk rather than on revised Gardasil demand assumptions.
• Buy medium-dated call spreads on MRK 6–9 months out only on a drawdown tied to adverse litigation headlines; the trade works if the market is pricing legal binary risk above the slower-moving revenue reality.
• Avoid shorting the vaccine cash-flow stream purely on Washington rhetoric; the better expression is a relative short in companies with direct exposure to falling adolescent preventive-care uptake, with a 12–24 month thesis rather than a tactical one.
• Set a watchlist for state-level HPV completion data over the next two reporting cycles; any inflection in completion rates is a cleaner catalyst for upside than the mortality headlines and would justify adding to longs.